Sep 17, 2020 / 02:00PM GMT
Louise Alesandra Chen - Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD
Hi, I am Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Merck.
Despite the impact COVID-19 has had on the industry, the underlying revenue growth for Merck's key products underscore that its oncology, vaccines, animal health and select hospital specialty care products as well as margin expansion opportunities remain underappreciated. Therefore, multiple expansion should drive Merck's shares higher as customer access gets better despite the ongoing pandemic and earnings visibility improves beyond the KEYTRUDA patent cliff in 2028.
Therefore, we're very excited to have with us Merck's Chief Marketing Officer, Mike Nally, today to discuss the future direction of the company.
Questions and Answers:
Louise Alesandra Chen - Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MDMike, it's not too early anymore to start thinking